Evidence map›Paper›PMID 38829880›Full record

Trial reportPLoS medicine2024

Effect of a multicomponent quality improvement strategy on sustained achievement of diabetes care goals and macrovascular and microvascular complications in South Asia at 6.5 years follow-up: Post hoc analyses of the CARRS randomized clinical trial.

Mohammed K Ali, Kavita Singh, Dimple Kondal, Raji Devarajan, Shivani A Patel, V Usha Menon, Premlata K Varthakavi, Vijay Vishwanathan, Mala Dharmalingam, Ganapati Bantwal and 7 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in PLoS medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01212328 (Developing and Testing Integrated, Multi-factorial Cardiovascular Disease Risk Reduction Strategies in South Asia), which is not on this map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01212328 naunknown statusnot on this map

Developing and Testing Integrated, Multi-factorial Cardiovascular Disease Risk Reduction Strategies in South Asia (CARRS Translation Trial)

TypeinterventionalSponsorPublic Health Foundation of IndiaRan2010 to 2014Enrolled1,120ConditionsType 2 Diabetes Mellitus, Hypertension, DyslipidaemiaArmsCare Coordinator + Decision Support Software, Usual care
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Education programmes for people with chronic kidney disease and diabetes.The Cochrane database of systematic reviews · 2024
    Pooled it
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mohammed K AliDepartment of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, Georgia, United States of America.ORCID 0000-0001-7266-2503
Kavita SinghHeidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.
Dimple KondalCentre for Chronic Disease Control, New Delhi, India.
Raji DevarajanPublic Health Foundation of India, Gurgaon, India.
Shivani A PatelDepartment of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, Georgia, United States of America.ORCID 0000-0003-0082-5857
V Usha MenonAmrita Institute of Medical Sciences, Department of Endocrinology & Diabetes, AIMS Ponekkara, Kochi, India.
Premlata K VarthakaviTNM College & BYL Nair Charity Hospital, Department of Endocrinology, Mumbai, India.
Vijay VishwanathanMV Hospital for Diabetes & Diabetes Research Centre, Chennai, India.
Mala DharmalingamBangalore Endocrinology & Diabetes Research Centre, Bangalore, India.ORCID 0000-0002-4213-0300
Ganapati BantwalSt. John's Medical College & Hospital, Department of Endocrinology, Bangalore, India.
Rakesh Kumar SahayOsmania General Hospital, Department of Endocrinology, Hyderabad, India.
Muhammad Qamar MasoodAga Khan University, Department of Medicine, Section of Endocrinology and Diabetes, Karachi, Pakistan.ORCID 0000-0002-0998-4347
Rajesh KhadgawatAll India Institute of Medical Sciences, Department of Endocrinology & Metabolism, Biotechnology Block, New Delhi, India.
Ankush DesaiGoa Medical College, Department of Endocrinology, Bambolim, India.
Dorairaj PrabhakaranCentre for Chronic Disease Control, New Delhi, India.ORCID 0000-0002-3172-834X
K M Venkat NarayanEmory Global Diabetes Research Center, Woodruff Health Sciences Center, Emory University, Atlanta, Georgia, United States of America.
Nikhil TandonAll India Institute of Medical Sciences, Department of Endocrinology & Metabolism, Biotechnology Block, New Delhi, India.ORCID 0000-0003-4604-1986

Funding

Fogarty International Clinical Research Scholars Support Center @ Vanderbilt-AAMCR24TW007988 · FIC · VANDERBILT UNIVERSITY · PI VERMUND, STEN H. · 2007 to 2011
$27.6M
Integrated Care for Co-morbid Depression and Diabetes in IndiaR01MH100390 · NIMH · EMORY UNIVERSITY · PI ALI, MOHAMMED KUMAIL, CHWASTIAK, LYDIA ANN · 2013 to 2017
$2.4M
Developing and testing Collaborative Quality ImProvement initiative (C-QIP) for prevention of cardiovascular disease in IndiaK43TW011164 · FIC · PUBLIC HEALTH FOUNDATION OF INDIA · PI SINGH, KAVITA · 2019 to 2023
$342k
FIC NIH HHS K43 TW011164FIC NIH HHS R24 TW007988NIMH NIH HHS R01 MH100390
6 · The paper itself

Abstract

backgroundDiabetes control is poor globally and leads to burdensome microvascular and macrovascular complications. We aimed to assess post hoc between-group differences in sustained risk factor control and macrovascular and microvascular endpoints at 6.5 years in the Center for cArdiovascular Risk Reduction in South Asia (CARRS) randomized trial. METHODS AND

findingsThis parallel group individual randomized clinical trial was performed at 10 outpatient diabetes clinics in India and Pakistan from January 2011 through September 2019. A total of 1,146 patients with poorly controlled type 2 diabetes (HbA1c ≥8% and systolic BP ≥140 mm Hg and/or LDL-cholesterol ≥130 mg/dL) were randomized to a multicomponent quality improvement (QI) strategy (trained nonphysician care coordinator to facilitate care for patients and clinical decision support system for physicians) or usual care. At 2.5 years, compared to usual care, those receiving the QI strategy were significantly more likely to achieve multiple risk factor control. Six clinics continued, while 4 clinics discontinued implementing the QI strategy for an additional 4-year follow-up (overall median 6.5 years follow-up). In this post hoc analysis, using intention-to-treat, we examined between-group differences in multiple risk factor control (HbA1c <7% plus BP <130/80 mm Hg and/or LDL-cholesterol <100 mg/dL) and first macrovascular endpoints (nonfatal myocardial infarction, nonfatal stroke, death, revascularization [angioplasty or coronary artery bypass graft]), which were co-primary outcomes. We also examined secondary outcomes, namely, single risk factor control, first microvascular endpoints (retinopathy, nephropathy, neuropathy), and composite first macrovascular plus microvascular events (which also included amputation and all-cause mortality) by treatment group and whether QI strategy implementation was continued over 6.5 years. At 6.5 years, assessment data were available for 854 participants (74.5%; n = 417 [intervention]; n = 437 [usual care]). In terms of sociodemographic and clinical characteristics, participants in the intervention and usual care groups were similar and participants at sites that continued were no different to participants at sites that discontinued intervention implementation. Patients in the intervention arm were more likely to exhibit sustained multiple risk factor control than usual care (relative risk: 1.77; 95% confidence interval [CI], 1.45, 2.16), p < 0.001. Cumulatively, there were 233 (40.5%) first microvascular and macrovascular events in intervention and 274 (48.0%) in usual care patients (absolute risk reduction: 7.5% [95% CI: -13.2, -1.7], p = 0.01; hazard ratio [HR] = 0.72 [95% CI: 0.61, 0.86]), p < 0.001. Patients in the intervention arm experienced lower incidence of first microvascular endpoints (HR = 0.68 [95% CI: 0.56, 0.83), p < 0.001, but there was no evidence of between-group differences in first macrovascular events. Beneficial effects on microvascular and composite vascular outcomes were observed in sites that continued, but not sites that discontinued the intervention.

conclusionsIn urban South Asian clinics, a multicomponent QI strategy led to sustained multiple risk factor control and between-group differences in microvascular, but not macrovascular, endpoints. Between-group reductions in vascular outcomes at 6.5 years were observed only at sites that continued the QI intervention, suggesting that practice change needs to be maintained for better population health of people with diabetes.

trial registrationClinicalTrials.gov NCT01212328.

Indexed as

Diabetes Mellitus, Type 2Quality ImprovementAdultAgedAsia, SouthernDiabetic AngiopathiesFemaleFollow-Up StudiesGlycated HemoglobinHumansIndiaMaleMiddle AgedPakistanRisk FactorsGlycated Hemoglobin

Identifiers

PMID38829880
PMCPMC11198027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.